Equity Overview
Price & Market Data
Price: $28.31
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $2,332,729,344
Daily Volume: 0
Performance Metrics
1 Week: 20.42%
1 Month: 6.47%
3 Months: -20.61%
6 Months: -25.62%
1 Year: 134.9%
YTD: -21.99%
Company Details
Employees: 76
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.